Publication: MCM2 expression levels predict diagnosis and prognosis in gastric cardiac cancer
Authors
Liu, Min ; Li, Jin-Song ; Tian, Dong-Ping ; Huang, Bo ; Rosqvist, Seema ; Su, Min
item.page.secondaryauthor
item.page.director
Publisher
F. Hernández y Juan F. Madrid. Universidad de Murcia. Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Background: Gastric Cardiac Cancer (GCC)
has high incidence and poor prognosis requiring early
screening of high-risk populations. Minichromosome
maintenance (MCM) proteins are used as diagnosticbiomarkers
in many cancers but not validated for GCC.
We evaluate MCM protein 2 (MCM2), comparing it with
the validated markers Ki67 and PCNA. Methods: GCC
and corresponding cardiac precancerous samples were
immunostained with Ki67, MCM2 and PCNA
antibodies. Results: 90% of dysplasia samples expressed
MCM2, whereas Ki67 and PCNA were expressed in
67% and 80% respectively. The sensitivity and negative
predictive values of MCM2 were also superior at 90%
and 87%, respectively. Ki67 and PCNA expression was
correlated with MCM2, but their expressions seldom
reached surface layers, whereas MCM2 manifested
mostly in easily accessible superficial layers. Labeling
indices (LI) of Ki67 and PCNA were also lower.
Significant associations between LI (MCM2), LI
(PCNA), and TNM-stages, lymph node metastases and
GCC grade were found (P<0.05). Increased protein
expressions were associated with reduced overall and
disease-free survival (P<0.05). Although Ki67 and
PCNA were significant prognostic factors, there was no
significant improvement in multivariate statistical
analyses, in contrast to LI (MCM2) findings.
Conclusions: MCM2 is a sensitive, specific and efficient
biomarker of GCC having potential use in clinic
publication.page.subject
Citation
Histology and histopathology, Vol. 28, n.º 4 (2013)
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.